drugset
Drugs / Ecnoglutide
last change Aug 2026 re-read 2 minutes ago

Ecnoglutide

also known as XW003 · Ecnoglutida · Ecnoglutide component of xw-004 · Ecnoglutide component of xw004 xw003

Protein / enzyme biologic

Developed for
obesity disorder · type 2 diabetes mellitus · obstructive sleep apnea syndrome
Investigated by
Hangzhou Sciwind Biosciences Co., Ltd. · Sciwind Biosciences APAC CO Pty. Ltd. · Sciwind Biosciences USA Co., Ltd.

Trials 12 · a red edge is where a trial was stopped

today NCT07434050 · Ph 3 NCT07387094 · Ph 3 NCT07243171 · Ph 1/2 NCT07143227 · Ph 1 NCT07073417 · Ph 2 NCT06335134 · Ph 1 NCT05813795 · Ph 3 NCT05680129 · Ph 3 NCT05680155 · Ph 3 NCT05184322 · Ph 1 NCT05111912 · Ph 2 NCT04389775 · Ph 1
202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT07143227 Aug 2025 → Apr 2026 obesity disorder Hangzhou Sciwind Biosciences Co., Ltd. Completed No outcome recorded
Phase 1 NCT06335134 Jul 2023 → Jan 2024 — Hangzhou Sciwind Biosciences Co., Ltd. Completed No outcome recorded
Phase 1 NCT05184322 Apr 2022 → Jul 2024 obesity disorder, type 2 diabetes mellitus Sciwind Biosciences APAC CO Pty. Ltd. Completed No outcome recorded
Phase 1 NCT04389775 Mar 2020 → Sep 2021 metabolic dysfunction-associated steatohepatitis, obesity disorder, type 2 diabetes mellitus Sciwind Biosciences APAC CO Pty. Ltd. Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT07243171 Nov 2025 → Aug 2026 overdue obesity disorder Hangzhou Sciwind Biosciences Co., Ltd. Recruiting No outcome recorded
Phase 22 trials
Phase 2 NCT07073417 Jul 2025 → Feb 2027 expected obesity disorder Hangzhou Sciwind Biosciences Co., Ltd. Active not recruiting No outcome recorded
Phase 2 NCT05111912 Nov 2021 → Nov 2022 obesity disorder Sciwind Biosciences APAC CO Pty. Ltd. Completed No outcome recorded
Phase 35 trials
Phase 3 NCT07434050 Mar 2026 → Jun 2028 expected obesity disorder, obstructive sleep apnea syndrome Hangzhou Sciwind Biosciences Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT07387094 Feb 2026 → Dec 2027 expected obesity disorder, obstructive sleep apnea syndrome Hangzhou Sciwind Biosciences Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT05813795 Apr 2023 → Jun 2024 — Hangzhou Sciwind Biosciences Co., Ltd. Completed No outcome recorded
Phase 3 NCT05680129 Jan 2023 → Jul 2024 type 2 diabetes mellitus Hangzhou Sciwind Biosciences Co., Ltd. Completed No outcome recorded
Phase 3 NCT05680155 Dec 2022 → Jun 2024 type 2 diabetes mellitus Hangzhou Sciwind Biosciences Co., Ltd. Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as ecnoglutide “Here we describe the discovery and characterization of ecnoglutide (XW003), a novel GLP-1 analog.” PMID 37364710 ↗ Jun 2023
5

NCT05680155 ↗

NCT05184322 ↗

NCT05813795 ↗

NCT05680129 ↗

NCT07243171 ↗
Known as Ecnoglutida ChEMBL registry synonym — accepted as the source's own label CHEMBL5095115 ↗
Known as Ecnoglutide component of xw-004 ChEMBL registry synonym — accepted as the source's own label CHEMBL5095115 ↗
Known as Ecnoglutide component of xw004 xw003 ChEMBL registry synonym — accepted as the source's own label CHEMBL5095115 ↗
Known as XW003 “Here we describe the discovery and characterization of ecnoglutide (XW003), a novel GLP-1 analog.” PMID 37364710 ↗ Jun 2023
6

NCT07434050 ↗

NCT06335134 ↗

NCT05111912 ↗

NCT07073417 ↗

NCT07143227 ↗

NCT07387094 ↗
Action Activate “ecnoglutide potently induced cAMP” PMID 37364710 ↗ Jun 2023
Modality Peptide “XW003 is an acylated human glucagon-like peptide 1 (GLP-1) analogue” NCT05111912 ↗
Modality Protein / enzyme biologic — CHEMBL5095115 ↗
Route Subcutaneous “subcutaneous ecnoglutide injection” PMID 37364710 ↗ Jun 2023